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Recombinant Enzyme Therapy for Fabry Disease: Absence of Editing of
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For more than a decade, protein-replacement therapy has been employed successfully for the treatment of Gaucher
disease. Recently, a comparable therapy has become available for the related lipid-storage disorder Fabry disease.
Two differently produced recombinant a-galactosidase A (a-gal A) preparations are used independently for this
purpose. Agalsidase a is obtained from human fibroblasts that have been modified by gene activation; agalsidase
b is obtained from Chinese hamster ovary cells that are transduced with human a-gal A cDNA. It has previously
been claimed that a-gal A mRNA undergoes editing, which may result in coproduction of an edited protein (Phe
396 Tyr) that might have a relevant physiological function. We therefore analyzed the occurrence of a-gal A editing,
as well as the precise nature, in this respect, of the therapeutic enzymes. No indications were obtained for the
existence of editing at the protein or RNA level. Both recombinant enzymes used in therapy are unedited and are
capable of functionally correcting cultured fibroblasts from Fabry patients in their excessive globotriaosylceramide
accumulation. Although RNA editing is apparently not relevant in the case of a-gal A, a thorough analysis of the
potential occurrence of editing of transcripts is nevertheless advisable in connection with newly developed protein-
replacement therapies.
Introduction
Fabry disease (MIM 301500) is an X-linked lysosomal
storage disorder caused by a deficiency of the lysosomal
enzyme a-galactosidase A (a-gal A). This defect results
in the progressive accumulation of glycosphingolipids in
lysosomes of endothelial, perithelial, and smooth muscle
cells of the vascular system, as well as renal epithelial
cells, myocardial cells, and cells of the autonomic ner-
vous system (Desnick et al. 1996). The accumulating
glycosphingolipids contain terminal a-galactosyl moie-
ties, such as globotriaosylceramide (Gb3); galabiosyl-
ceramide (Gb2); and, to a lesser extent, blood group B,
B1, and P1 antigens (Martensson 1966; Wherrett and
Hakomori 1973; Desnick et al. 1996) Fabry disease pa-
tients suffer from angiokeratomas, acroparesthesias, cor-
neal dystrophy, renal failure, and myocardial and cere-
bral infarction, resulting in premature mortality. Since
the a-gal A gene is located on the X chromosome (locus
Xq22), all hemizygous males suffer from Fabry disease,
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although the majority of female heterozygous carriers
also display attenuated forms of the disease. Gaucher
disease, a related glycolipid storage disorder caused by
a deficiency of the lysosomal b-glucocerebrosidase, can
be treated by chronic intravenous administration of the
enzyme (Barton et al. 1991). This so-called enzyme-re-
placement therapy is found to be remarkably effective
for the non-neuronopathic variant of Gaucher disease,
resulting in reversal of the major clinical symptoms. A
comparable approach has recently been applied to the
treatment of Fabry disease. Two differently produced
enzyme preparations have independently been examined
in clinical investigations: enzyme produced by Chinese
hamster ovary (CHO) cells with classic recombinant
technology (agalasidase b, Fabrazyme) and enzyme pro-
duced by cultured human skin fibroblasts with an ac-
tivated promoter of the a-gal A gene (agalasidase a,
Replagal). In both studies, promising lipid substrate re-
ductions in tissue biopsies have been observed (Eng et
al. 2001; Pastores and Thadhani 2001; Schiffmann et
al. 2001) Very recently, both recombinant products have
been registered by the European Medical Evaluation
Agency (EMEA) in Europe, and their registration in the
United States is pending.
The a-gal A protein is composed of two identical
subunits of ∼49 kDa and is encoded by a mature tran-
script of 1,350 nucleotides (Calhoun et al. 1985; Bishop
et al. 1986). Interestingly, the human a-gal A mRNA
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previously has been reported to undergo RNA editing:
a uridylate residue at position 1187 of the mature tran-
script is converted to an adenylate residue (Novo et al.
1995). The result of this nucleotide conversion would
be an amino acid substitution (Phe 396 Tyr) in the C-
terminal part of the encoded protein, which theoreti-
cally could lead to two a-gal A proteins with different
functions or modes of regulation in the human body.
Examples of such a “single gene, multiple proteins” sce-
nario have been described in detail for several human
genes (for comprehensive reviews, see Chang et al.
[1998] and Rueter and Emeson [1998]). For example,
the human ApoB mRNA, L-glutamate receptor subunit
mRNAs and serotonin receptor subunit mRNAs have
all been shown to undergo different forms of RNA ed-
iting, resulting in the translation of different protein
isoforms with different functions or physical properties
in the human body (Chen et al. 1987; Powell et al. 1987;
Burns et al. 1997). The report claiming the existence of
editing of the human a-gal A transcript has so far ap-
parently not raised concerns, despite the fact that it may
have important implications for the products used in
enzyme-replacement therapy for Fabry disease. The
mRNA produced by gene activation in human fibro-
blasts should undergo editing. In the case of the class-
ic recombinant technology using transduction with
cDNA, the occurrence of RNA editing can not be pre-
dicted. We therefore studied the natural occurrence of
“edited” a-gal A mRNA to gain insight into the bio-
logical significance of RNA editing of a-gal A in hu-
mans. Moreover, the editing status of the two thera-
peutic enzyme preparations was investigated.
Material and Methods
Isolation and Culturing of Human Macrophages and
Fibroblasts
Human peripheral blood monocytes were isolated and
cultured as described elsewhere (Hollak et al. 1994).
Spontaneous differentiation of monocytes into activated
macrophages occurs on prolonged cell culture (Hollak
et al. 1994). Human skin fibroblasts were cultured as
described elsewhere (Wanders et al. 1992).
RNA and DNA Isolation
Total RNA from macrophages was isolated by use of
the RNAzol B RNA isolation kit (Tel-Test), as described
elsewhere (Boot et al. 1998). Total RNA from fibroblasts
was isolated as described in (IJlst et al. 1994). DNA was
isolated according to standard protocols (Sambrook et
al. 1989).
Amplification of DNA and RNA Fragments (RT-PCR)
For PCR amplification of DNA fragments, the follow-
ing protocol was used: 1 ng of recombinant DNA or
500 ng of total human DNA was incubated with 20
pmol oligonucleotides for 3 min at 94C, after which it
was amplified in 35 cycles of 30 s at 94C, 30 s at 48C,
and 1 min at 72C. The exact annealing temperature
depended on the length and GC content of the oligo-
nucleotides used in a particular experiment: 4C per G
or C, plus 2C per A or T, minus 5C. For these reactions,
1 U of Taq polymerase and buffers were used according
to the manufacturer’s instructions (Promega).
For amplification of RNA segments (RT-PCR), the
PCR protocol was preceded by cDNA synthesis: 1 mg
oligo (dT)12–18 was added to 10 mg of human total RNA,
was denatured for 4 min at 74C, and then was im-
mediately put on ice and added to the RTmix containing
1# first strand buffer, 10 mMDTT, 500 mMeach dNTP,
20 U of RNAsin (Promega), and 200 U Superscript II
(Gibco BRL) in a total volume of 30 ml. The mixture
was incubated for 2 h at 45C, followed by 5 min at
95C; 1 ml of the mixture was used for PCR, essentially
as described above.
Oligonucleotides used were: DB001S, GAATTCACC-
ATGCAGCTGAGGAACCCAGA; DB002S, GAATTC-
CTGGACAATGGATTGGCAAGG; DB003AS, GAAT-
TCTTAAAGTAAGTCTTTTAATGACAT; DB005S, G-
CAGGCTTCCCTGGGAGT; DB006AS, TAAAGGAG-
CAGCCATGATAGC; DB007S, CCTCTGCATTGATA-
ACTGTTGGATGGCTCCCC; DB008AS, GGGGAGC-
CATCCAACAGTTATCAATGCAGAGG; DB009S,
GGAAGCTAGGGTACTATGAATGGACTTCAAGG;
DB010AS, CCTTGAAGTCCATTCATAGTACCCTAG-
CTTCC; and DB011AS, TTGCGGCCGCTTAAAGTA-
AGTCTTTTAATGACAT. Underlined nucleotides indi-
cate mismatches introduced for site-directed mutagenesis
(see below).
Cloning of the Human a-gal A cDNA
The complete ORF encoding human a-gal A (includ-
ing the signal peptide sequence; see Genbank accession
number gi:3808177) was amplified in an RT-PCR pro-
cedure, making use of the oligonucleotides DB001S and
DB011AS (see above). The amplified fragment was
cloned into the pGEM-T vector (Promega), and positive
clones were digested with EcoRI andNotI. The resulting
1,299-bp EcoRI-NotI fragment was then cloned into
pcDNA3.1() (Invitrogen), which had been digested
with EcoRI and NotI, resulting in plasmid pDB007.
Site-Directed Mutagenesis and Sequencing of Clones
Site-directed mutagenesis was performed by use of the
QuikChange Site-DirectedMutagenesis Kit (Stratagene).
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In short, this procedure made use of plasmid pDB007,
which contains the correct full-length a-gal A ORF. In
this clone, the edited sequence was introduced artificially
by use of the oligonucleotides DB009S and DB010AS
(see above; mutated nucleotides underlined). The re-
sulting clone was named pDB009. The catalytically in-
active a-gal A clone was generated according to the same
procedure, making use of the oligonucleotides DB007S
and DB008AS (see above; mutated nucleotides under-
lined). The resulting clone was named “pDB008” and
encodes an a-gal A protein that contains an asparagine
residue instead of an aspartate residue at position 93.
Nucleotide sequences of both strands of positive
clones were verified by use of universal M13 primers
and the oligonucleotides listed above, on an Applied
Biosystems 377A automated DNA sequencer, following
ABI protocols.
Expression of Recombinant Proteins in COS-1 Cells
Transient transfection of COS-1 cells with different
a-gal A constructs was performed by the DEAE-Dextran
method, essentially as described elsewhere (Lopata et al.
1984).
Therapeutic Enzymes
Agalsidase a (Replagal, TKT) and agalsidase b (Fa-
brazyme, Genzyme) were obtained from the local hos-
pital pharmacy.
Enzyme Activity Measurement
The enzymatic activity of a-gal A was measured using
the fluorogenic substrate 4-methylumbelliferyl-a-D-gal-
actopyranoside (4-MU-galactopyranoside, Sigma), es-
sentially as described elsewhere (Ioannou et al. 1992).
In brief, 25 ml of cleared medium was incubated with
100 ml reaction mixture containing the 4-MU substrate
(final concentration 3.5 mM) in 100 mM citrate/200
mM phosphate buffer pH 4.6, at 37C, for 1 h. Reac-
tions contained 100 mM N-acetylgalactosamine to in-
hibit a-galactosidase B activity (Mayes et al. 1981). Re-
actions were terminated by the addition of 2 ml 300
mM Glycine/NaOH buffer, pH 10.6, and fluorescent 4-
methyl-umbelliferone was measured with a fluorimeter
(Perkin-Elmer) at 445 nm.
Specific activity of the commercial a-gal A prepara-
tions was determined using the protein measurement
procedure by Lowry with human albumin as reference
protein. Specific activity of a-gal A enzyme produced in
COS-1 cells was determined following 10% SDS-
PolyAcrylAmide gel electrophoresis and silverstaining
with a commercial a-gal A preparation (Agalsidase b,
Fabrazyme, Genzyme) as reference protein.
Globotriaosylceramide (Gb3) Measurement
The levels of Gb3 in fibroblasts were determined fol-
lowing lipid extraction of harvested cells using the thin
layer chromatographic procedure described by Desnick
and coworkers (1971).
Generation and Purification of Antibodies
280 mg of recombinant human a-gal A protein (Gen-
zyme), either native or denatured, was used to immunize
rabbits. Generated antibodies were purified by the use
of a MAbTrap G II column (Pharmacia Biotech), ac-
cording to the manufacturer’s instructions. This proce-
dure made use of Protein G, which has affinity for rabbit
IgGs, coupled to a Sepharose matrix.
Purification of Human a-gal A
Human a-gal A was comparably purified from various
sources (culture media of transfected COS-1 cells; urine
samples from a healthy male) by use of sequential con-
canavalin A sepharose column chromatography, im-
munoaffinity precipitation, and preparative isoelectric
focusing. In brief, fractions containing enzyme activity
were concentrated using the Amicon Diaflo system, with
a 10-kDa cutoff membrane, and were washed with a
100-mM potassium-phosphate buffer, pH 6.5, contain-
ing 50 mM NaCl (buffer A). The concentrated fractions
were next applied to a 30-ml ConA-Sepharose column
that had been equilibrated with buffer A. Unbound pro-
teins were removed by washing with 10-column volumes
of buffer B (100 mM potassium phosphate pH 6.5; 500
mM NaCl). Bound proteins were eluted from the ConA
column with buffer B containing 100 mM methylman-
noside and were collected in 1-ml fractions. Fractions
containing a-gal A activity were pooled and concen-
trated using Millipore Ultrafree-MC centrifugal filter
units with a molecular cutoff of 10 kDa. This concen-
trated material was then subjected to immunoprecipi-
tation using anti-galactosidase A antiserum covalently
coupled to CNBr-activated Sepharose 4B according to
the manufacturer’s instructions (Pharmacia Biotech). Af-
ter extensive washing in phosphate buffered saline, the
bound enzyme was released by incubation in 0.1M citric
acid (pH 3.5). Following neutralization with potassium
phosphate buffer, the fraction was subjected to prepar-
ative isoelectric focusing, using Servalyt 4-9 T (Serva) as
carrier ampholytes. After focusing, the gel was divided
into 30 fractions, and proteins were extracted by the
addition of 1 ml water followed by centrifugation. The
supernatants were then tested for a-gal A activity.
Determination of Amino Acid Sequences of a-gal A
For matrix-assisted laser desorption ionization
(MALDI) analysis, protein-containing gel slices were S-
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Figure 1 Apparent absence of a-gal A mRNA editing. RT-PCR
followed by RsaI digestion of macrophage- and fibroblast-derived
RNA. A, Schematic overview of expected RsaI digestion fragment
pattern. B, lanes 1 and 2, patterns for fibroblasts of two control sub-
jects; lanes 3–5, patterns for macrophages of three control subjects.
alkylated, were digested with trypsin (Boehringer-Mann-
heim, sequencing grade), and were extracted (Shev-
chenko et al. 1996). Only the peptides eluted with 20
mM NH4HCO3 were used in the MALDI analysis. After
drying in a vacuum centrifuge, the peptides were dis-
solved in 10 ml 60% acetonitrile, 1% formic acid. 0.5
ml of this solution was mixed with 0.5 ml of a solution
of 52 mM a-cyano-4-hydroxycinnamic acid in 49% eth-
anol/49% acetonitrile/2% TFA and 1 mM ammonium
acetate. Prior to dissolving, the a-cyano-4-hydroxycin-
namic acid (Sigma) was washed briefly with acetone. The
mixture was spotted on a targetplate and allowed to dry
at room temperature. Reflectron MALDI-TOF spectra
were acquired on a Micromass Tof Spec 2EC (Micro-
mass). The resulting peptide spectra were used to search
a nonredundant protein sequence database (SWISS-
PROT/TREMBL) using the Protein Probe program.
Results
Occurrence of Edited a-gal A Transcripts in Humans
The reported editing of human a-gal A mRNA in-
volves a single-nucleotide conversion in the 3′ end of the
coding region (nucleotide 1187; see Novo et al. 1995).
To investigate the frequency of the editing phenomenon,
we performed RT-PCR analyses on mRNA isolated from
macrophages and fibroblasts from different individuals.
To be sure that transcripts encoded by a single gene were
analyzed, only RNA isolated from males was analyzed.
As outlined in figure 1, an 870-bp fragment of the a-
gal A mRNA was amplified that subsequently was di-
gested with RsaI and was examined on agarose gels.
Since the described conversion of uridylate residue 1187
into an adenylate residue should give rise to the creation
of an additionalRsaI restriction site, amplified fragments
containing the edited nucleotide sequence should be dis-
criminated in this analysis (fig. 1A). However, no diges-
tion fragments derived from edited a-gal A mRNA were
detected in any of the macrophage RNA samples (fig.
1B, lanes 3–5; note the absence of DNA fragments of
203 and 110 bp). Since Novo et al. reported editing
levels of 63% for a-gal A mRNA isolated from fibro-
blasts, our RT-PCR analyses also included two fibroblast
RNA samples as positive controls (lanes 1 and 2). Also
these RNA samples did not show the presence of di-
gested PCR fragments derived from edited a-gal A
mRNA (fig. 1B). The unexpected result could not be
attributed to an inactive RsaI enzyme, since RsaI diges-
tion fragments from unedited a-gal A mRNA were de-
tectable. This finding therefore rather suggested that the
investigated macrophages and fibroblasts seemed to be
devoid of edited a-gal A mRNA (fig. 1B).
The analysis of the editing status of fibroblast a-gal
A mRNA was further extended. We isolated mRNA
from fibroblasts of 10 different males and amplified part
of the a-gal A mRNA containing the putative editing
site. From each amplified mRNA fragment, the nucle-
otide sequence of at least 10 independent clones was
determined. This extensive analysis made clear that none
of the amplified a-gal A mRNA fragments contained an
edited sequence, indicating that a-gal A mRNA is most
likely not edited in the fibroblasts from the 10 donors
tested (table 1).
Analysis of a-gal A Protein by MALDI Mass
Spectrometry
The two commercial a-gal A preparations were in-
vestigated by mass spectrometry as described in the
“Material and Methods” section. Identical results were
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Table 1
Analysis of a-gal A mRNA Editing in Independent
Fibroblast and Macrophage Clones
Male
RNA
Source
No. of
Clones
Sequenced
No. of Clones
in Unedited/Edited
Sequence
M Fibroblast 24 24/0
97-3138 Fibroblast 10 10/0
92-052 Fibroblast 10 10/0
98-335 Fibroblast 10 10/0
96-229 Fibroblast 10 10/0
99-3138 Fibroblast 10 10/0
92-137 Fibroblast 10 10/0
90-225 Fibroblast 10 10/0
94-285 Fibroblast 10 10/0
98-361 Fibroblast 10 10/0
WDJ Macrophage 29 29/0
obtained for both preparations. As illustrated in figure
2B and table 2, a peptide mass fingerprinting analysis
clearly identified 13 tryptic peptides derived from a-gal
A (giving a coverage of 24%). The part of the protein
derived from the putative editing domain (see fig. 2A
and 2B) could easily be detected. It was observed as two
peptide peaks at mass/charge (m/z) values of 1,158.54
and 1,286.64, caused by the presence of an additional
lysine residue at the N-terminus of one of the two pep-
tides (fig. 2C and table 2). This pattern is often found
when trypsine is confronted with two successive basic
residues (in this instance, RK). These two peptides were
clearly derived from unedited a-gal A mRNA sequences
(see table 1). The peptides derived from the “edited”
protein sequence (fig. 2A) would be expected at m/z
values of 1,174 and 1,302 (table 1). However, as can be
seen in the enlarged mass spectrum (fig. 1C), these pep-
tides could not be detected. Since the predicted peptides
result from a very minor, FrY change in the middle of
the peptides, we would not expect this absence to be
due to a difference in efficiency of ionization or recovery
of the respective peptides. This seems especially true in
the light of the fact that more profound differences—like
the absence of the N-terminal lysine residue in one of
the peptides—do not lead to clear differences in ioni-
zation or recovery of these peptides. These results show
that both a-gal A enzyme preparations do not contain
“edited” a-gal A protein.
Generation of “Edited” a-gal A Protein and
Comparison with Other Enzyme Preparations
A cDNA construct was generated that contained the
edited a-gal A nucleotide sequence (see the “Material
and Methods” section for details). In parallel, COS-1
cells were transfected with either a construct containing
the normal a-gal A nucleotide sequence (clone pDB007)
or a construct containing an a-gal A nucleotide sequence
with a point mutation in the putative catalytic site (clone
pDB008 [Zeidner et al. 1993]) as positive and negative
controls, respectively. Expression in COS-1 cells of the
construct containing the putative catalytic-site mutation
did not result in the synthesis of catalytically active a-
gal A protein (pDB008). Expression of the construct
containing the edited a-gal A nucleotide sequence
(pDB009), however, led to the synthesis of normal
amount of catalytically active a-gal A protein. Enzyme
in the medium of the transfected COS-1 cells with wild-
type and “edited” a-gal A cDNA was next purified by
sequential concanavalin A chromatography, anti a-gal
A immunoprecipitation, and isoelectric focusing. The
specific activity of the wild-type and “edited” (Phe 396
Tyr) a-gal A produced in COS-1 cells was similar (4.1
 0.4 # 106 and 4.0  0.2 # 106 nmol/mg/h (mean
 SD), respectively). The specific activity was compa-
rable to that of the two therapeutic enzyme preparations
agalsidase a (Replagal) and agalsidase b (Fabrazyme),
being 4.7  0.5 # 106 and 4.9  0.5 # 106 nmol/
mg.hour, respectively.
Functional Correction of Fabry Fibroblasts by a-gal A
Preparations
Cultured fibroblasts from normal subjects and two
patients with Fabry disease were incubated for 3 h, with
either agalsidase a or agalsidase b preparation (0.1mmol
substrate hydrolysis per h), in the absence or presence
of 5 mM mannose phosphate. Next, the medium was
changed, and cells were harvested after extensive wash-
ing. The cellular a-gal A activity was determined. Table
3 shows the results of one such experiment mimicking
enzyme-replacement therapy. Similar data were obtained
in two other, independent experiments with cells derived
from four different patients. As can be seen in table 3,
the uptake of enzyme from both commercial prepara-
tions was highly similar and almost completely inhibited
by the presence of mannose-6-phosphate in the culture
medium. Impressive corrections in cellular a-gal A ac-
tivity levels were observed in the Fabry fibroblasts even
after a 3-d delay. In both enzyme preparations, cellular
a-gal A activity was always at least 20%–30% of that
immediately after the pulse labeling of the Fabry fibro-
blasts ( , in three independent experiments). More-np 4
over, the enzyme uptake resulted in functional correction
as illustrated by the marked reduction in Gb3 levels. In
fibroblasts from one patient with Fabry disease, the lipid
level was reduced by 86% and 82% following exposure
to agalsidase a and b preparations (0.1 mmol/h for 3
h), respectively. In fibroblasts from another patient with
Fabry disease, the reductions were 72% and 70%,
respectively.
Figure 2 Recombinant a-galactosidase contains only “unedited” peptide sequence. A, Schematic representation of the editing site of
human a-gal A mRNA and the resulting amino acid change. B, Full mass spectrum of agalsidase b. The X-axis indicates mass/charge values
(m/z); the Y-axis indicates the relative intensity of detected ions (%). Identified peptides derived from a-gal A are indicated with their mass
value. C, Enlargement of the 1,130–1,330 m/z range of panel B, with the isotopic distribution around the m/z 1,158.54 and 1,286.64 peaks.
X-axis and Y-axis as in panel B.
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Table 2
Identification of Peptide Sequences of Recombinant Human a-gal A
Predicted
Molecular
Weight
Observed
Molecular
Weight Sequence
726.3973 726.36 (R)FPHGI R(Q)
764.3977 764.35 (K)QGYQL R(Q)
1,063.4454 1,063.42 (R)QYCNH WR(N) 
1,158.5505 1,158.54 (K)LGFYE WTSR(L)
1,286.6455 1,286.64 (R)KLGFY EWTSR(L) *
1,413.6659 1,413.67 (R)TPTMG WLHWE R(F)
1,429.6608 1,429.63 (R)TPTMG WLHWE R(F) #
1,495.7103 1,495.73 (K)SILDW TSFNQ ER(I)
1,534.8164 1,534.84 (R)LQADP QRFPH GIR(Q) *
1,951.0785 1,951.07 (K)ALLQD KDVIA INQDP LGK(Q) *
2,044.0758 2,044.07 (K)GVACN PACFI TQLLP VKR(K) *  
2,058.1278 2,058.01 (K)GVACN PACFI TQLLP VKRK(L) **
2,696.4657 2,996.44 (K)ALLQD KDVIA INQDP LGKQG YQLR(Q) **
1,174.5499 Not found (K)LGYYE WTSR(L) @
1,302.6449 Not found (R)KLGYYE WTSR(L) @
NOTE.—Indicated are molecular weights of peptides predicted on the basis of
the a-gal A cDNA sequence and the molecular weights obtained by mass spec-
trometry. Shown in the right column are the amino acid sequences that comply
with the observed masses; parentheses indicate neighboring amino acids that are
not part of the peptide. The last two predicted molecular weights are based on
the putative edited sequence of the a-gal A mRNA sequence (see fig. 1a). Symbols:
 p carboxyamidomethylcysteine(s); * p missed cleavage(s); # p methionine
sulfoxide; @ p “Edited” peptide.
Table 3
Correction of Cellular a-gal A Activity Following Exposure to
Recombinant Enzyme Preparations
SOURCE OF
FIBROBLASTS
ENZYME ACTIVITY
(nmol/h/mg protein)
Agalsidase a Agalsidase b
No Enzyme M6P M6P M6P M6P
Control subject 1 240 4,300 810 3,900 790
Control subject 2 285 3,560 620 3,500 710
Patient 1 25 4,640 955 3,360 680
Patient 2 11 3,105 720 3,700 605
NOTE.—Cells were incubated for 3 h with 0.1 # 106 nmol/h a-gal
A activity. Enzyme activity in cell extracts was determined as described
in the “Material and Methods” section.
Discussion
Fabry disease is an X-linked lysosomal storage disorder
that affects ∼1/40,000 newborns (Desnick et al. 1996).
Protein-replacement therapy using recombinant a-gal A
is considered to allow correction of the harmful lyso-
somal accumulation of glycosphingolipids containing
terminal a-galactosyl moieties in various cell types of
patients with Fabry disease. Obviously, the quality of
the enzyme product used in such replacement therapy is
of key importance. In this connection, it is surprising
that little attention has been paid to the report by Novo
et al. (1995) that a-gal A mRNA undergoes RNA ed-
iting. On the basis of their findings, two distinct a-gal
A proteins could, in theory, be encoded by a single a-
gal A gene, with each of them having different physical
properties and possibly different functions in the human
body. At present, two different a-gal A preparations are
employed that are produced by two entirely different
techniques. Agalsidase a, produced by human fibroblasts
following gene activation, could theoretically undergo
editing. In contrast, agalsidase b, which is produced by
transduction of Chinese hamster ovary cells with cDNA,
can only undergo editing if this form of editing does not
require the presence of intron sequences (compare Rue-
ter and Emeson 1998). It is therefore of the utmost im-
portance to know precisely which a-gal A protein forms
are administered during replacement therapy and
whether different a-gal A isoforms with different func-
tions exist in vivo. In the present article, we report that
both recombinantly produced a-galactosidases A used
for therapy contain the unedited amino acid sequence
only. Both recombinant enzyme preparations can func-
tionally correct cultured fibroblasts from patients with
Fabry disease, causing a correction in Gb3 lipid levels.
Our investigation also found no evidence for the ex-
istence of a-gal A editing in humans. This could be
concluded from a detailed study of the editing status of
human a-gal A transcripts. According to Novo et al.
(1995), 40%–60% of the a-gal A transcripts isolated
30 Am. J. Hum. Genet. 72:23–31, 2003
from fibroblast, muscle, and cerebellum contain the ed-
ited nucleotide sequence. In contrast, our RT-PCR anal-
yses of macrophage and fibroblast RNA from different
male individuals revealed no edited a-gal A transcripts.
This was further substantiated by the a-gal A nucleo-
tide-sequence determination of at least 10 independent
clones obtained from fibroblast RNA from 10 differ-
ent male individuals each (totalling 1130 independent
cDNA clones). These data—and the fact that a-gal A
editing would involve the only known instance of UrA
base conversion, for which no simple enzymatic path-
way can be envisaged—lead us to conclude that a-gal
A transcripts are not edited. Further support for this
absence of editing of a-gal A transcripts comes from
EST databases. Currently, the human EST database at
the National Center for Biotechnology Information
Web site contains over 60 a-gal A tags from different
human tissues, of which 44 contain the putative editing
domain. Of these 44 tags, however, none contains the
edited sequence as reported by Novo et al. (1995). The
reason for the discrepancy between our data and those
of Novo and coworkers is hard to identify. One possible
explanation would be the existence of polymorphic se-
quences in the a-gal A gene. Sequencing of the corre-
sponding cDNA would then lead one to conclude (in-
correctly) that the mRNA is edited, when compared to
genomic database sequences. Novo and coworkers,
however, compared their cDNA sequences with ge-
nomic sequences obtained from the same individual,
making this explanation unlikely. A more plausible ex-
planation would be that Novo et al. (1995) picked up
a cDNA fragment containing a PCR mistake that con-
taminated subsequent PCR reactions. Such a contami-
nation would be difficult to detect in cDNA PCR am-
plifications and cannot be detected in the genomic PCR
reactions as carried out by Novo et al., since their ap-
proach makes use of primers that are specific for ge-
nomic sequences, not cDNA sequences.
In conclusion, our data show that patients with Fabry
disease currently receive therapy with unedited a-gal A
protein only and that edited a-gal A transcripts do not
occur in humans in vivo. Although RNA editing is ap-
parently not relevant in the case of a-gal A, it has to
be realized that a thorough analysis of the potential
occurrence of editing of transcripts is nevertheless
advisable in connection with protein-replacement
therapies.
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